PAUL SHESLOW: Open Payments
NPI 1295201994 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$219 in 11 payments from 8 companies in 2025. Trend: 2023 $937 · 2024 $889 · 2025 $219
Food & beverage: $219
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $60 |
| Lundbeck LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Bausch Health US, LLC | 1 | $20 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
Products named: Auvelity, REXULTI, TRINTELLIX, CAPLYTA, APLENZIN, INGREZZA, LYBALVI, Qelbree.
Industry payments across DE — which companies pay providers there.
